US pharma major AbbVie (NYSE: ABBV) announced financial results for the first quarter of 2024, showing that worldwide net revenues were $12.310 billion, an increase of 0.7% on a reported basis, or 1.6% on an operational basis.
The figure was 3% above consensus analysts forecast, but AbbVie’s shares had declined more than 4% to $160.32 by late-morning trading.
Adjusted diluted earnings per share (EPS) were $2.30, down 6.1%, but 2% above consensus, driven by lower financial expenses. Net earnings attributable to AbbVie were $1,369 million, compared to $239 million in the like 2023 quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze